Peptron's stock has sharply declined amid concerns regarding its collaboration with Eli Lilly.
As of 1:26 PM on July 10, shares of Peptron were trading at 111,900 won, down 47,400 won (29.76%) from the previous trading day. At the start of the session, the stock fell to the lower limit of 111,600 won.
The market reaction is attributed to comments made by Peptron CEO Choi Ho-il, which were interpreted as dampening expectations for the development of a monthly GLP-1 obesity treatment.
During the Shinhan Bio Forum held the previous day, Choi stated that “Tirzepatide is not included” in the collaboration with Eli Lilly. Tirzepatide is the active ingredient in Lilly's obesity and diabetes treatments, Mounjaro and Zepbound.
In response, Peptron clarified that the recent controversy stemmed from a misunderstanding, as only certain aspects of the collaboration were highlighted, rather than the entire scope. The ongoing research is not focused on a single commercial product but is proceeding as planned across multiple pipelines.
Meanwhile, Peptron entered into a Material Transfer Agreement (MTA) with Eli Lilly in October 2024 to conduct joint research. This study aims to verify the potential for developing a long-acting formulation using smart depot technology applied to Eli Lilly's peptide candidates.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.